Many DSOs expanded quickly during the zero-rate era, but integration often did not keep pace. As capital costs rise, fragmented systems, manual processes and decentralized operations are becoming harder to ignore. For today’s DSOs, the pressure is no longer just…
Presented by:
Early signs of conditions like dementia are often first observed in primary care. Yet confirming and documenting those changes still relies on overextended specialists and time-intensive evaluations. The result: delayed detection, unnecessary referrals and missed opportunities for early intervention. In…
On Demand
Presented by:
Dr. Anthony Zizza
Chief Medical Officer, Element Care
Julie Miyamasu
Clinical Strategy Director, Care Transformation, Advocate Health
Professor Adrian Owen
Cognitive Neuroscientist and Chief Scientific Officer, Creyos
Oklahoma City-based Oklahoma Children’s Hospital has become the first facility in Oklahoma to offer a targeted chemotherapy treatment for retinoblastoma, according to a March 9 report KOCO News. The treatment delivers chemotherapy directly to the patient’s eye via catheter, bypassing…
Most virtual health pilots fail not because of the technology — but because of how they’re architected from the start. Without defined exit criteria, integration benchmarks, or measurable system impact, even promising pilots stall before reaching production. This session brings…
On Demand
Presented by:
Jason Ward
VP of Information Systems Collette Health
Maruf Haider, MD
Associate Chief Medical Information Officer, Digital Health Carilion Clinic
Alen Oganesyan, MPA, CHCIO, CDH-E
Associate Chief Information Officer Keck Medicine of USC
Albert Villarin, MD, MBA, FACEP
VP, Chief Medical Informatics Officer Nuvance/Northwell Health
Greta Branford, MD
ACMIO, Associate Medical Director for Healthcare IT, Michigan Medicine
Seattle-based Fred Hutch Cancer Center has appointed Mazyar Shadman, MD, and Vyshak Alva Venur, MD, as deputy chief medical officers. Both have served as interim deputy chief medical officers since September, according to a March 10 LinkedIn post from the…
The FDA has approved a new device to treat adults with locally advanced pancreatic cancer in combination with gemcitabine and nab-paclitaxel. The device called Optune Pax, is a portable, wearable system that uses low-intensity electric fields to disrupt cancer cell…
Boston-based Massachusetts General Hospital — part of Somerville, Mass.-based Mass General Brigham — has received $35 million from Irving Oil to fund two cancer-focused facilities within the Phillip and Susan Ragon Building, currently under construction. The funds will establish the…
For decades, cancer care has advanced through new therapies, technologies and molecular insights. But beneath every treatment decision, prognosis and research breakthrough sits a quieter constant: staging. Rick Greene, MD, FACS, emeritus chair of surgery at Carolinas Medical Center and…
New York City-based New York-Presbyterian Hudson Valley Hospital will pay $6.8 million to resolve allegations it improperly paid a Westchester, N.Y.-based oncology practice to induce referrals later billed to Medicare and Medicaid, according to a Dec. 22 Justice Department news…
AstraZeneca’s LATIFY phase 3 trial evaluating ceralasertib in combination with Imfinzi did not meet its primary endpoint of overall survival in patients with advanced non-small cell lung cancer. Ceralasertib is an oral ATR kinase inhibitor designed to enhance anti-tumor immune…
